Abstract:Objective: The aim of this study is to investigate the clinical factors in association with venous thromboembolism (VTE) in patients with lung cancer, and to provide evidence for prevention and therapy of VTE. Methods: Clinical information of 2 053 patients with lung cancer definitely diagnosed by cytology or pathology between July 2008 and June 2010 was retrospectively analyzed. VTE wasconfirmed by chest spiral computed tomography (CT), pulmonary arteriography and colorful Dopplerultrasound. The clinical factors including age, gender, pathological type, operation, clinical stage,body mass index, co-morbidity and platelet count as well as D -dimer, interleukin-1 (IL-1) and tumornecrosis factor (TNF) were considered as the potential VTE-related factors. Results: Of 2 053 patients,89 (4.34%) were confirmed with VTE. The incidence rates of VTE in patients with adenocarcinoma andnon-adenocarcinoma were 5.65% (58/1 027) and 3.02% (31/1 026), respectively, and the difference wasstatistically significant (P £?0.003). The incidence rate of VTE in stage I-III A lung cancer patients was significantly lower than that in stage IIIB-IV lung cancer patients [1.48% (10/677) vs 5.74% (79/1 376); P<0.001]. In patients with stage I-IIIA undergoing surgical operation or not, the incidence rates of VTE were 1.55% (10/645) and 0% (0/32), respectively (P=0.044). Significant difference of incidence rate of VTE was also found between the patients with and without co-morbidity [6.73% (56/832) vs 2.70% (33/ 1 221); P<0.001]. The incidence rates of VTE in patients with normal levels of platelet count, D -dimer,IL-1 and TNF were 3.72%, 0.31%, 2.44% and 3.27%, respectively; whereas, the incidence rates in patients with increased levels of these measurements were 6.26%, 19.91%, 10.26% and 7.74%, respectively; the differences between two groups were all significant (P<0.05). Logistic multivariant regression analysisrevealed that the clinical factors of adenocarcinoma, operation, co-morbidy and high levels of D-dimer,IL-1 and TNF in blood were associated with increased risk of VTE (P<0.05). Conclusion: Adenocarcinomais the most common pathological type in lung cancer patients with VTE. The risk factors of VTE include operation, co-morbidity and high levels of D -dimer, IL-1 and TNF in blood. Copyright© 2011 by TUMOR.

Management of Venous Thromboembolism in Patients with Lung Cancer: a State-of-the-art Review

Venous thromboembolism in non-small-cell lung cancer patients:Report of 15 cases

Risk Factors and Prognosis Value of Venous Thromboembolism in Patients with Advanced Non-Small Cell Lung Cancer: a Case-Control Study

Prevalence and clinical characteristics of venous thromboembolism in patients with lung cancer: a systematic review and meta-analysis

Advances in the Prediction and Risk Assessment of Lung Cancer-Associated Venous Thromboembolism

A Lung Cancer Patient with Deep Vein Thrombosis:A Case Report and Literature Review

Diagnosis and Treatment Characteristics of Lung Cancer Patients with Venous Thromboembolism

Lung Cancers Combined With Venous Thromboembolism: A Case Report

Venous Thromboembolism in Lung Cancer with Clinical Analysis of 89 Cases

[Retrospective Analysis of Risk Factors for Venous Thromboembolism in 283 Patients with Lung Cancer During Systemic Therapy].

Prophylaxis and Treatment of Venous Thromboembolism in Cancer Patients: a Systemic Review and Critical Appraisal of Clinical Practice Guidelines

The Society for Translational Medicine: the Assessment and Prevention of Venous Thromboembolism after Lung Cancer Surgery

Postoperative venous thromboembolism in patients with lung cancer

Comparison among Different Presentations of Venous Thromboembolism Because of Lung Cancer

Current status of treatment of cancer-associated venous thromboembolism

[Current Status of Prevention and Nursing on Venous Thromboembolism among Perioperative Patients with Lung Cancer].

Risk Factors and Prediction Models for Venous Thromboembolism in Ambulatory Patients with Lung Cancer

Clinical Analysis of Postoperative Venous Thromboembolism Risk Factors in Lung Cancer Patients

A systematic review of risk prediction model of venous thromboembolism for patients with lung cancer

Venous thromboembolism in 89 patients with lung cancer: clinical analysis

Management of venous thromboembolism in patients with cancer